Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [BUSINESS]
2 clusters · 2 sources · 4 days · First seen · Last updated
Staar Surgical market activity and analyst updates
Overview
Staar Surgical has experienced positive market momentum driven by corporate financial decisions and favorable analyst assessments.
On September 25, the company announced a $50 million share buyback program, authorized by its Board of Directors. CEO Warren Foust indicated the move reflects confidence in the company’s business progress and balance sheet, stating the company is currently “substantially undervalued.” Following this announcement, the stock price rose by more than 7%.
On September 29, shares rose further following an upgrade from Stifel, which moved the eyecare company from a ‘hold’ to a ‘buy’ rating and increased the price target from $28 to $31. Analyst Thomas Stephan attributed expected sales growth in the first half of 2026 to demand for surgically implanted lenses in China, while also noting the company’s potential as an acquisition target.
Entities
Timeline
-
[BUSINESS] 2 sourcesStaar Surgical shares rise following analyst upgrade
Staar Surgical shares climbed approximately 8% on Tuesday after Stifel upgraded the eyecare company to a 'buy' rating with a $31 price target, citing strong sales potential in China.
-
[BUSINESS] 2 sourcesStaar Surgical announces $50 million share buyback program
Staar Surgical announced a $50 million share buyback program, citing undervaluation and strong cash flow. The company's stock rose over 7% following the news.
Sources
stocknews.com · theascent.com